Spironolactone
Spironolactone has been studied in 60 papers since 1999: 8 trials and 23 observational studies in people, 4 in animals, 23 reviews; 35 in the past year. It is an approved medicine. The newest paper, Nov 16, 2026: “Cardioprotective Interventions During Anthracycline-Based Chemotherapy: A Systematic Review and Network Meta-Analysis”.
20 new papers in 30 daysSee all 80 papers on spironolactone
At a glance
Spironolactone extends lifespan in klotho-hypomorphic mice in one group's study; a human trial reports lower mortality in older women with HFpEF. Reviews describe independently replicated ejection-fraction improvements in chemotherapy-treated breast cancer patients; another human trial shows no clear frailty benefit in HFpEF. Trials report hyperkalemia; some papers declare company ties, and some trials are Pfizer-sponsored.
40 findings in 28 papers from 1993 to 2026, 8 of them since May 2026
Independent labs found the same change in people. 22 independent labs in 11 countries; 127 trials, 3 about aging, 34 with no results posted.
“Randomization to active therapies increased the percentage of TIR across trials, by 3% (95%CI −1 to 7%) with spironolactone”
None of its findings points the other way.
- 22 independent labs in 11 countries
- 127 trials, 3 about aging, 34 with no results posted
- Funders: National Natural Science Foundation of China and others
- 6 of 36 findings with company ties
- 2 of 127 trials sponsored by its developers
- Human trial8
- Humans22
- Animals4
Studies in people
See all 7 studies of spironolactone in people7 studies gave spironolactone to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
up: Increases time in target systolic blood pressure range3% (95% CI −1 to 7%) | Review of trialsfirst year | 18,823 people pooledBothmean age 72±9 yearsOlder adults; Heart failure with LVEF ≥45%; target systolic blood pressure 110–<130 mmHg | ESC Congress 2026 abstract, Oct 26, 2026 |
up: Increases discontinuation due to hyperkalemia | Randomized trial72 weeks | 168 peopleelderlyOlder adults; on irbesartan background therapy | The American journal of the medical sciences, May 20, 2026 |
no change: Has no effect on health status | Randomized trial9 months | 527 peopleBothmedian 73 yearsOlder adults; Patient cohorts | Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology, Mar 21, 2026 |
down: Decreases PICP | Randomized trial9 months | 488 peopleIn patients at risk of heart failure | MedComm, Feb 17, 2026 |
down: Lowers the risk of mortality10.0 vs. 7.3%, HR 0.68, 95% CI 0.48–0.96 | Treated cohortabout 3.3 years | 1,619 people898 (55.5%) were women, and 721 (44.5%) were men≥70 yearsElderly heart failure patients with preserved ejection fraction | Frontiers in cardiovascular medicine, Oct 4, 2021 |
What did studies of spironolactone find?
29Studies of spironolactone measured 29 outcomes, among them left ventricular ejection fraction, home systolic blood pressure and systolic blood pressure.
Left ventricular ejection fraction
upin humans2
2 studies
Left ventricular ejection fraction
upin humans2
Spironolactone increases left ventricular ejection fraction in humans (receiving anthracycline-based chemotherapy; compared with Control) (MD 12.08 percentage points, 95% CrI 3.57–20.65).
Reviewreceiving anthracycline-based chemotherapy; compared with Controlheart
Spironolactone increases left ventricular ejection fraction in humans (breast cancer patients undergoing chemotherapy; compared with placebo) (MD 12.80; 95% CrI 5.99 to 19.60).
Reviewbreast cancer patients undergoing chemotherapy; compared with placeboheart
Home systolic blood pressure
downin humans1
1 study
Home systolic blood pressure
downin humans1
Spironolactone decreases home systolic blood pressure in humans (Resistant hypertension; versus placebo in PATHWAY-2) (8.70 mmHg versus placebo; 4.48 mmHg versus bisoprolol).
ReviewResistant hypertension; versus placebo in PATHWAY-2
Systolic blood pressure
downin humans1
1 study
Systolic blood pressure
downin humans1
Spironolactone decreases systolic blood pressure in humans (resistant hypertension) (-20.1 mmHg (95% CI -31.2 to -9.1)).
Reviewresistant hypertensionn = 230
Apnea-hypopnea index
downin humans1
1 study
Apnea-hypopnea index
downin humans1
Spironolactone decreases apnea-hypopnea index in humans (obstructive sleep apnea; compared with placebo) (MD −22.68 events/h; 95% CI, −25.42 to −19.93).
Reviewobstructive sleep apnea; compared with placebo
Time in target systolic blood pressure range
upin humans1
1 study
Time in target systolic blood pressure range
upin humans1
Spironolactone increases time in target systolic blood pressure range in humans (Heart failure with LVEF ≥45%; target systolic blood pressure 110–<130 mmHg) (3% (95% CI −1 to 7%)).
Human trialHeart failure with LVEF ≥45%; target systolic blood pressure 110–<130 mmHgfirst year
Auditory thresholds
downin mice1
1 study
Auditory thresholds
downin mice1
Spironolactone impairs auditory thresholds in mice (attenuated benefits of Dkk3 knockdown or aldosterone supplementation).
Animalsattenuated benefits of Dkk3 knockdown or aldosterone supplementation
Discontinuation due to hyperkalemia
upin humans1
1 study
Discontinuation due to hyperkalemia
upin humans1
Spironolactone increases discontinuation due to hyperkalemia in humans (on irbesartan background therapy).
Human trialon irbesartan background therapy20 mg/d72 weeks
Serum potassium
upin humans1
1 study
Serum potassium
upin humans1
Spironolactone increases serum potassium in humans (on irbesartan background therapy).
Human trialon irbesartan background therapy20 mg/d72 weeks
Systolic blood pressure
downin humans1
1 study
Systolic blood pressure
downin humans1
Spironolactone decreases systolic blood pressure in humans (compared with placebo in resistant hypertension) (-13.3 mm Hg (95% CI, -17.89 to -8.72)).
Reviewcompared with placebo in resistant hypertension25-50 mg/dn = 3,485
Health status
no changein humans1
1 study
Health status
no changein humans1
Spironolactone showed no clear effect on health status in humans.
Human trial9 months
PICP
downin humans1
1 study
PICP
downin humans1
Spironolactone decreases PICP in patients at risk of heart failure.
Human trialin patients at risk of heart failure
Frailty
no changein humans1
1 study
Frailty
no changein humans1
Spironolactone showed no clear effect on frailty in patients with heart failure with preserved ejection fraction (aOR 0.85, 95% CI 0.67 to 1.09).
Human trialin patients with heart failure with preserved ejection fraction1-yearn = 1,767
Outcomes by frailty class (no interaction between frailty and treatment effect)
no changein humans1
1 study
Outcomes by frailty class (no interaction between frailty and treatment effect)
no changein humans1
Spironolactone showed no clear effect on outcomes by frailty class (no interaction between frailty and treatment effect) in HFpEF patients across frailty classes.
Human trialin HFpEF patients across frailty classesn = 1,767
Arterial stiffness
no changein humans1
1 study
Arterial stiffness
no changein humans1
Spironolactone showed no clear effect on arterial stiffness in humans (older adults with stable compensated HFpEF).
Human trialolder adults with stable compensated HFpEF25 mg/d9 months
Blood pressure
downin humans1
1 study
Blood pressure
downin humans1
Spironolactone decreases blood pressure in humans (older adults with stable compensated HFpEF).
Human trialolder adults with stable compensated HFpEF25 mg/d9 months
All 29Fewer
What is spironolactone linked with?
8Studies link spironolactone with 8 measures, among them mortality, composite adverse cardiovascular events and annual rate of estimated glomerular filtration rate decline.
Mortality
downin humans2HR 0.68
2 studies
Mortality
downin humans2HR 0.68
Spironolactone lowers the risk of mortality in women (10.0 vs. 7.3%, HR 0.68, 95% CI 0.48–0.96).
Human trialin womenabout 3.3 yearsn = 898
Spironolactone lowers the risk of mortality in humans (elderly HFpEF) (HR 0.68, 95% CI 0.48-0.96).
Human trialelderly HFpEFfemales
Spironolactone lowers the risk of mortality in humans (HR 0.68, 95% CI 0.48-0.96).
Human trialelderly patients with HFpEF (TOPCAT); no significant sex-treatment interaction (p interaction=0.190)femalesn = 898
Composite adverse cardiovascular events
downin humans1HR 0.7
1 study
Composite adverse cardiovascular events
downin humans1HR 0.7
Spironolactone lowers the risk of composite adverse cardiovascular events in humans (heart failure) (HR: 0.70).
Reviewheart failure4–44 months
Annual rate of estimated glomerular filtration rate decline
upin humans1
1 study
Annual rate of estimated glomerular filtration rate decline
upin humans1
Spironolactone is associated with annual rate of estimated glomerular filtration rate decline in humans (Type 2 diabetes and persistent proteinuria despite SGLT2i therapy) (Median annual eGFR change from -2.2 to 1.3 mL/min/1.73 m2/year; p=0.001).
HumansType 2 diabetes and persistent proteinuria despite SGLT2i therapyMonths 3–12 after spironolactone initiationn = 29
Urinary protein-to-creatinine ratio
downin humans1
1 study
Urinary protein-to-creatinine ratio
downin humans1
Spironolactone is associated with urinary protein-to-creatinine ratio in humans (Type 2 diabetes and persistent proteinuria despite more than six months of SGLT2i therapy) (Median UPCR decreased from 0.70 to 0.15 g/g creatinine).
HumansType 2 diabetes and persistent proteinuria despite more than six months of SGLT2i therapy12 monthsn = 29
Adverse effects
upin humans1
1 study
Adverse effects
upin humans1
Spironolactone is linked with a higher risk of adverse effects in humans (doses >50 mg vs <=50 mg in primary aldosteronism) (39.1% vs 29.3%).
Humansdoses >50 mg vs <=50 mg in primary aldosteronismn = 394
Fall risk
upin humans1OR 4.1
1 study
Fall risk
upin humans1OR 4.1
Spironolactone is linked with a higher risk of fall risk in humans (older adults) (OR = 4.10, p = 0.001).
Humansolder adultsn = 200
Osteoporosis
downin humans1OR 0.385
1 study
Osteoporosis
downin humans1OR 0.385
Spironolactone is linked with a lower risk of osteoporosis in middle-aged and elderly hypertensive patients (post-match: OR 0.385, 95% CI, 0.259-0.571).
Humansin middle-aged and elderly hypertensive patients
Community-acquired hyperkalemia
upin humans1OR 2.53
1 study
Community-acquired hyperkalemia
upin humans1OR 2.53
Spironolactone is associated with community-acquired hyperkalemia in humans (OR 2.530).
Humans
Has spironolactone been tested in people?
3 of 127 about agingYes: 8 trials and 23 observational studies in people have been published, and 127 trials are registered.
About aging
Statin Combined With Amlodipine Treats Primary Aldosteronism
Phase 4Active, not recruiting
SCREEN-HFI (SCReening Evaluation of the Evolution of New Heart Failure Intervention Study)
Phase 3Completed
Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Dementia
Phase 4Completed
Approved
Jan 21, 1960Edema, Heart Failure, Hypertension, Nephrotic Syndrome, heart failure and reduced ejection fraction, cirrhosis of the liver, high blood pressure, primary hyperaldosteronism, hepatic cirrhosis
Aug 4, 2017Edema, Heart Failure, Hypertension, high blood pressure, heart failure and reduced ejection fraction, Cirrhosis
May 26, 2023Edema, Heart Failure, Liver Cirrhosis, Ascites, Nephrotic Syndrome, Hyperaldosteronism, Essential Hypertension, primary aldosteronism, congestive cardiac failure, malignant ascites, hepatic cirrhosis
Repurposing
Phase 4Status unknown2 trials
Phase 4Results posted1 trial
Phase 4Completed1 trial
Phase 4Completed4 trials
Phase 4Status unknown1 trial
Phase 3Completed1 trial
40 of 72Fewer
Every condition in trials
Hypertension Resistant to Conventional Therapy
Phase 4Completed3 trials
Autosomal dominant polycystic kidney
Phase 3Results posted1 trial
Aml
Phase 1/2Completed1 trial
Leukemia myeloid acute
Phase 1/2Status unknown1 trial
Alcohol drinking
Phase 1Recruiting1 trial
Bioequivalence study
Phase 1Completed1 trial
Readouts due
- Dec 31, 2026
Spironolactone in Alcohol Use Disorder (SAUD)
Phase 1Recruiting
- May 1, 2027
- Aug 1, 2027
Stopped
NCT03597035TerminatedHyperkalemia
The study could not enroll patients owing to the inclusion exclusion criteria
NCT03777319TerminatedDuchenne muscular dystrophy
Inability to recruit participants.
NCT01843309Terminated
Not possible to complete the sample within the estimated time by the use of new antifungals
Who is developing spironolactone?
3 companies: CMP Development, AstraZeneca and Sarfez Pharmaceuticals.
Trial sponsors
Company2 trialsPhase 4618 people
Company2 trialsPhase 4124 people
Company1 trialPhase 4388 people
Company1 trialPhase 324 people
Company2 trialsPhase 2387 people
Company2 trialsPhase 1/278 people
Company1 trialPhase 1/268 people
Company2 trialsPhase 154 people
Funding
1 grant since 2025American Heart Association
How this record changed
Summary written from the findings.